Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...

OliX Pharmaceuticals, the first Asian company to advance its own proprietary RNA interference (RNAi) technology platform into the clinic, is using RNAi technology to treat skin, eye and lung diseases.